Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.The most common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain. Sacituzumab govitecan has a boxed warning about the risk of severe neutropenia (abnormally low levels of white blood cells) and severe diarrhea. Sacituzumab govitecan may cause harm to a developing fetus or newborn baby. Women are advised not to breastfeed while on sacituzumab govitecan and one month after the last dose is administered.The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider it to be a first-in-class medication. Sacituzumab govitecan was approved for medical use in the European Union in November 2021. Medical uses
Sacituzumab govitecan is indicated for the treatment of adults with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease; people with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease; and for people with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. Administration
Sacituzumab govitecan is given in a 21-day treatment cycle in which an injection is only given a few days of the cycle.
Recent research by Krystel R. Huxlin and others on the relearning of complex visual motion following V1 damage has offered potentially promising treatments for individuals with acquired cortical blindness. These treatments focus on retraining and retuning certain intact pathways of the visual cortex which are more or less preserved in individuals who sustained damage to V1. Huxlin and others found that specific training focused on utilizing the "blind field" of individuals who had sustained V1 damage improved the patients ability to perceive simple and complex visual motion. This sort of relearning therapy may provide a good workaround for patients with acquired cortical blindness in order to better make sense of the visual environment. See also
Blindsight

References
Further reading
Books
Vighetto, A., & Krolak-Salmon, P. (2007). Cortical blindness. New York, NY: Cambridge University Press. Papers
Balliet, R., Blood, K. M., & Bach-y-Rita, P. (1985). Visual field rehabilitation in the cortically blind? : Journal of Neurology, Neurosurgery & Psychiatry Vol 48(11) Nov 1985, 1113-1124. Trevethan, C. T., & Sahraie, A. (2003). Spatial and temporal processing in a subject with cortical blindness following occipital surgery: Neuropsychologia Vol 41(10) 2003, 1296-1306. == External links ==